Results 101 to 110 of about 70,337 (231)

Metabolome analysis identified exogenous cholesterol within lipid rafts that activate the Akt/mTOR signaling pathway in epithelial ovarian cancer

International Journal of Cancer, EarlyView.
What's New? Epithelial ovarian cancer (EOC) is a severe malignancy with few effective treatment options. While the mechanisms remain unclear, changes in lipid metabolism may fuel tumor growth and EOC progression, offering a possible path for new treatments.
Hitomi Sakaguchi‐Mukaida, Kosuke Hiramatsu, Tatsuo Masuda, Mamoru Kakuda, Satoshi Nakagawa, Tadashi Iwamiya, Shinya Matsuzaki, Tetsuji Naka, Yutaka Ueda, Tadashi Kimura, Michiko Kodama   +10 more
wiley   +1 more source

DNA repair in cancer: emerging targets for personalized therapy [PDF]

, 2014
Genomic deoxyribonucleic acid (DNA) is under constant threat from endogenous and exogenous DNA damaging agents. Mammalian cells have evolved highly conserved DNA repair machinery to process DNA damage and maintain genomic integrity.
Abbotts, Rachel, Madhusudan, Srinivasan, Thompson, Nicola   +2 more
core   +3 more sources

The clinical development of inhibitors of poly(ADP-ribose) polymerase

Annals of Oncology, 2011
A number of inhibitors of DNA repair have been evaluated or are undergoing development as potential cancer treatments. Inhibitors of poly(ADP-ribose) polymerase (PARP) are of particular interest in treating hereditary breast cancers occurring in patients who are carriers of BRCA1 or BRCA2 mutations. In vitro PARP inhibitors are highly cytotoxic to cell
H, Calvert, A, Azzariti
openaire   +2 more sources

Treatment patterns and clinical outcomes in real‐world patients with small‐cell lung cancer in South Korea: A single‐center experience

International Journal of Cancer, EarlyView.
What's New? The emerging role of immunotherapy in small‐cell lung cancer treatment has not been fully elucidated, particularly outside of clinical trials. This single‐center retrospective cohort study examined real‐world treatment patterns and overall survival in South Korea during the 2018–2023 period.
Sehhoon Park, Danbee Kang, Jin Lee, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Hojoon Lee, Hyuna Lim, Xerxes Pundole, Juhee Cho, Myung‐Ju Ahn   +11 more
wiley   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. [PDF]

, 2015
BACKGROUND: Personalized therapy considering clinical and genetic patient characteristics will further improve breast cancer survival. Two widely used treatments, chemotherapy and radiotherapy, can induce oxidative DNA damage and, if not repaired, cell ...
Aittomäki, Kristiina, Alnæs, Grethe G, Behrens, Sabine, Blomqvist, Carl, Bolla, Manjeet K., Børresen-Dale, Anne-Lise, Chang-Claude, Jenny, Couch, Fergus J., Dunning, Alison M., Easton, Doug F, Fagerholm, Rainer, Flesch-Janys, Dieter, Hall, Per, Hamann, Ute, Hartikainen, Jaana M., Hollestelle, Antoinette, Hooning, Maartje J, Humphreys, Keith, Jager, Agnes, Kabisch, Maria, Kataja, Vesa, Kosma, Veli-Matti, Kristensen, Vessela, Lambrechts, Diether, Li, Jingmei, Liu, Jianjun, Mannermaa, Arto, Margolin, Sara, Michailidou, Kyriaki, Nevanlinna, Heli, Nord, Silje, Pharoah, Paul, Popanda, Odilia, Purrington, Kristen S, Rhenius, Valerie, Schildkraut, Joellen M, Schmezer, Peter, Schmidt, Marjanka K., Seibold, Petra, Seynaeve, Caroline, Shah, Mitul, Torres, Diana, Ulmer, Hans-Ulrich, Wang, Qin, Wildiers, Hans   +44 more
core   +4 more sources

Beyond Tradition: An Integrated Toxicological, Ecological, and Public Health Perspective on Aristolochic Acids

Journal of Applied Toxicology, EarlyView.
ABSTRACT Aristolochia species have long been used in traditional medicine for their presumed anti‐inflammatory, analgesic and antimicrobial properties. However, extensive toxicological and epidemiological evidence now demonstrates that these plants contain aristolochic acids (AAs) I and II, highly potent nephrotoxic, genotoxic, and carcinogenic ...
Victor Ventura de Souza, Lara Rodrigues De Andrade, Tatiana da Silva Souza   +2 more
wiley   +1 more source

Is there an epigenetic component underlying the resistance of triple-negative breast cancers to PARP inhibitors?

Frontiers in Pharmacology, 2012
Poly(ADP-ribose)polymerase (Parp) is an enzyme responsible for catalyzing post-translational modifications through the addition of poly(ADP-ribose) chains (known as PARylation).
Amanda eLovato, Lawrence ePanasci, Michael eWitcher   +2 more
doaj   +1 more source

Multi‐Omics Profiling Uncovers Predictive Factors for Tumor‐Infiltrating Lymphocyte Therapy in Ovarian Cancer

Journal of Clinical Laboratory Analysis, EarlyView.
We profiled tumors from 10 ovarian cancer patients with whole‐exome sequencing (WES), bulk RNA‐seq, and single‐cell RNA‐seq to uncover predictors of successful tumor‐infiltrating lymphocyte (TIL) isolation and expansion. TIL+ tumors exhibited enriched CD8+ Teff/Tem populations with distinctive metabolic activity, dendritic‐cell–skewed myeloid states ...
Xiuzhen Wang, Rui Hou, Jinguo Chen, Bo He, Peiwen Liu, Genhai Zhu, Lan Hong, Wenjun Zhu   +7 more
wiley   +1 more source

Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis [PDF]

, 2018
Amyotrophic lateral sclerosis (ALS) is a devastating and fatal motor neuron disease. Diagnosis typically occurs in the fifth decade of life and the disease progresses rapidly leading to death within ~ 2–5 years of symptomatic onset. There is no cure, and
A Chiarugi, A Chiarugi, A Sonnenblick, AA Fatokun, AC Elden, AE Renton, AK Leung, B Luscher, B Nefussy, BA Gibson, C Benkler, C Cosi, C Culmsee, C Hewitt, C Vance, CR Calabrese, D Petrov, DR Rosen, DR Thal, E Bentmann, E Kiskinis, E Turunc Bayrakdar, EM Park, EV Hobson, F Geser, F Moroni, G Kim, GE Abdelkarim, GM Shah, Group AS, Group AS, H Braak, H Braak, H Farmer, H Kawamitsu, H Sawada, H Yokoyama, HE Bryant, HJ Kim, HT Chung, IG McKeith, IR Mackenzie, J Brettschneider, J Mojsilovic-Petrovic, J Mojsilovic-Petrovic, J Rosenfeld, J Sreedharan, J Zhang, JC Morris, JD Rothstein, JD Rothstein, JD Rothstein, JP Taylor, JS Bae, K Takahashi, K Uryu, K Zhang, KW Caldecott, L Lehtio, L Liu-Yesucevitz, L Mariotti, L McGurk, L Van Den Bosch, LA Becker, LP Rowland, M Altmeyer, M Citarelli, M DeJesus-Hernandez, M Endres, M Endres, M Hasegawa, M Isabelle, M Naumann, M Neumann, M Neumann, M Neumann, MA Farg, MJ Finelli, MO Hottiger, NA Berger, NL Kedersha, O Hardiman, O Spreux-Varoquaux, OA Andreassen, P Anderson, PJ Shaw, PL Oliver, R Gupte, R Krishnakumar, RH Tan, S Hanai, S Martire, S Martire, S Saxena, SA Andrabi, SB Gibson, SC Ling, SH Kaufmann, SH Kim, SH Kim, SH Koh, SL Rulten, SS Mirra, T Haikarainen, TJ Kwiatkowski Jr, TM Kauppinen, V Schreiber, VL Dawson, X Luo, Y Wang, YH Chung, YR Li, ZY Abd Elmageed   +112 more
core   +2 more sources